Consensus Statement Issued for Low-Dose Oral Minoxidil for Hair Loss
By Elana Gotkine HealthDay Reporter
THURSDAY, Nov. 21, 2024 -- Consensus has been reached for 76 items relating to low-dose oral minoxidil (LDOM) treatment for patients with hair loss, according to a statement published online Nov. 20 in JAMA Dermatology.
Yagiz Matthew Akiska, from the George Washington University School of Medicine & Health Sciences in Washington, D.C., and colleagues created an expert consensus statement for LDOM prescribing for patients with hair loss. Forty-three hair loss specialist dermatologists from 12 countries participated in a modified Delphi process, which started with 180 items in the first round.
Seventy-six items achieved consensus, which was reached if at least 70 percent agreed or strongly agreed. The authors noted that these items included diagnoses for which LDOM may provide direct or supportive benefit, indications for LDOM versus topical minoxidil, dosing for adults and adolescents, contraindications, precautions, baseline evaluation, monitoring, adjunctive therapy, and specialty consultation. Consensus was not achieved for pediatric use and dosing items for children younger than 12 years or for LDOM titration protocols.
"This consensus statement contributes substantially to the current understanding of LDOM prescribing for patients with hair loss, providing a solid foundation for clinical practice," the authors write. "These consensus recommendations serve as a crucial reference for dermatologists treating patients with hair loss, offering best-practice insights into LDOM prescribing until further data emerge."
Several authors disclosed ties to the pharmaceutical, skin care, and medical technology industries.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted November 2024
Read this next
Low-Dose Doxycycline Effective for Lymphocytic Scarring Alopecias
FRIDAY, March 21, 2025 – Relative to high-dose doxycycline, low-dose doxycycline is comparably effective but more tolerable for lymphocytic scarring alopecias...
American Academy of Dermatology, March 7 to 11
The annual meeting of the American Academy of Dermatology was held from March 7 to 11 in Orlando, Florida, and attracted clinicians, academicians, allied health...
AAD: Baricitinib Efficacious for Hair Regrowth in Teens With Severe Alopecia Areata
TUESDAY, March 18, 2025 -- For adolescents with severe alopecia areata (AA), baricitinib is efficacious for hair regrowth, according to a study presented at the annual meeting of...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.